WuXi Biologics and Pall Corporation Establish Joint Continuous Bioprocess Laboratory
Working together to develop next-generation biopharmaceutical manufacturing technologies that may reduce costs of novel antibodies to less than 15 USD/g.
Shanghai, November 2, 2017 — WuXi Biologics (2269.HK), a global leading open-access biologics technology platform company offering end-to-end solutions for biologicsdiscovery, development and manufacturing, and its partner Pall Corporation, the global leader of advanced filtration, separation and purification technologies, established a joint laboratory to develop full continuous processing for the manufacturing of monoclonal antibodies (mAb). The 3-year project started with the continuous operation of individual processes and will gradually be expanded to downstream processing development and production. The joint laboratory will serve WuXi Biologics’ customers worldwide in an attempt to significantly reduce mAb drugs’ manufacturing costs and benefit patients around the world.
An opening ceremony for the WuXi Biologics and Pall joint laboratory was held by the two parties on November 2, 2017. Attending the ceremony were Dr. Chris Chen, CEO of WuXi Biologics; Mr. Peter Shen, Vice President of WuXi Biologics; Mr. Rainer Blair, Executive Vice President of Danaher Life Sciences and Ms. Jennifer Honeycutt, President of Pall Corporation.
The joint laboratory, constructed with Pall Life Sciences’ unique CadenceTM Integrated Continuous Bioprocess System and integrated with its single-use technology platform, ensures process flexibility, facilitates switches between processes and avoids cross-contamination, thereby enabling pharmaceutical companies to reduce the manufacturing space required at a facility and to reduce cost.
After years of intensive efforts on technological development, WuXi Biologics has developed high-yielding cell lines and laboratory-scale continuous processes, significantly increasing the expression of some mAbs to up to equivalent of 40-50 g/L in the traditional fed-batch process, which is approximately 10 times more productive than the typical fed-batch process. Moving forward, the teams will improve large-scale purification equipment and technology that often becomes a bottleneck in continuous processing and will work to resolve the bottleneck. With this joint laboratory, WuXi Biologics plans to soon expand the continuous process scale to 500 L and reduce mAbmanufacturing cost to 30-50 USD/g, and then scale up to 1000 L and further reduce costs to less than 15 USD/g.
“As the solution provider of biopharmaceutical processes, Pall offers complete process development, as well as equipment and technical support needed for continuous bio-manufacturing—solutions that reduce costs for biopharmaceutical process development and production, and that enhance core competencies for biopharmaceutical companies. We’re excited about this new partnership with WuXi Biologics– they have a strong global influence which will help accelerate the development and innovation of advanced bioprocesses,” said Jennifer Honeycutt, President of Pall Corporation.
“WuXi Biologics is committed to further accelerating our expansion in capabilities and capacities, strengthening our leadership position as the most comprehensive and integrated enabling platform, empowering anyone and any company to discover, develop and manufacture biologics,” said Dr. Chris Chen, CEO of WuXi Biologics. “The partnership with Pall helps us utilize the global innovation and leading technology to effectively resolve bottlenecks of continuous processing, to significantly lower the cost of biologics and benefits patients worldwide.”
About WuXi Biologics
WuXi Biologics, a Hong Kong-listed company, is a leading global open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics, please visit www.wuxibiologics.com.
Pall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide. Follow more information visit www.pall.com or www.pall.cn.
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in some of the most demanding and attractive industries, including health care, environmental and industrial. With more than 20 operating companies, Danaher’s globally diverse team of over 62,000 associates is united by a common culture and operating system, the Danaher Business System. For more information, please visit www.danaher.com.